Quarter Period Statement Of Income

Sumitomo Pharma Co., Ltd. - Filing #7249083

Concept 2024-04-01 to
2025-03-31
2024-04-01 to
2025-03-31
2024-04-01 to
2025-03-31
2024-04-01 to
2025-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
Quarter period statement of income
Statement of income
Net sales
136,412,000,000 JPY
98,205,000,000 JPY
Cost of sales
60,097,000,000 JPY
61,232,000,000 JPY
Gross profit (loss)
76,315,000,000 JPY
36,973,000,000 JPY
Selling, general and administrative expenses
64,712,000,000 JPY
86,977,000,000 JPY
Selling, general and administrative expenses
Salaries
8,995,000,000 JPY
11,214,000,000 JPY
Depreciation
2,027,000,000 JPY
2,127,000,000 JPY
Operating profit (loss)
11,603,000,000 JPY
-50,004,000,000 JPY
Non-operating income
Non-operating income
10,446,000,000 JPY
48,224,000,000 JPY
Non-operating expenses
Interest expenses
4,348,000,000 JPY
3,106,000,000 JPY
Non-operating expenses
10,021,000,000 JPY
4,747,000,000 JPY
Ordinary profit (loss)
12,028,000,000 JPY
-6,527,000,000 JPY
Extraordinary income
Gain on sale of non-current assets
4,614,000,000 JPY
JPY
Extraordinary income
115,090,000,000 JPY
22,800,000,000 JPY
Extraordinary losses
Loss on sale of non-current assets
991,000,000 JPY
JPY
Impairment losses
1,044,000,000 JPY
JPY
Extraordinary losses
13,127,000,000 JPY
594,841,000,000 JPY
Profit (loss) before income taxes
113,991,000,000 JPY
-578,568,000,000 JPY
Income taxes - current
203,000,000 JPY
386,000,000 JPY
Income taxes - deferred
7,601,000,000 JPY
9,166,000,000 JPY
Income taxes
7,804,000,000 JPY
9,552,000,000 JPY
Profit (loss)
106,187,000,000 JPY
106,187,000,000 JPY
106,187,000,000 JPY
106,187,000,000 JPY
-588,120,000,000 JPY
-588,120,000,000 JPY
-588,120,000,000 JPY
-588,120,000,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.